In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

The Senate Health, Education, Labor and Pensions Committee yesterday voted to advance a vote on President Donald Trump's ...

Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines, and Pad Chivukula of ...

Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 ...

Moderna (MRNA) stock rises as the company's Spikevax COVID-19 vaccine gets FDA approval for kids 6 months-11 years at higher ...

Short sellers started to panic in recent days. Moderna (MRNA), which has a short interest of 16.44%, might benefit from two ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.

The U.S. Centers for Disease Control and Prevention ended its emergency response for bird flu as the outbreak that sickened ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.